Unicycive Therapeutics (UNCY) Liabilities and Shareholders Equity (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $64.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 130.46% year-over-year to $64.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $194.1 million (up 35.87% YoY) and the FY2025 annual result came in at $49.1 million, up 55.16% from the prior year.
• Liabilities and Shareholders Equity climbed to $64.4 million in Q1 2026, from $49.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $64.4 million in Q1 2026 to a low of $2.8 million in Q4 2022.
• A 5-year average of $30.3 million and a median of $27.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 1303.72% in 2022, down 84.97% in 2022.
• Tracing UNCY's Liabilities and Shareholders Equity over 5 years: stood at $2.8 million in 2022, then jumped by 403.58% to $14.2 million in 2023, then surged by 123.16% to $31.7 million in 2024, then surged by 55.16% to $49.1 million in 2025, then soared by 31.08% to $64.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $64.4 million (Q1 2026), $49.1 million (Q4 2025), and $50.6 million (Q3 2025), per Business Quant data.